Dear All,
I would like to bring you up to date on a natural evolution of Exactis Innovation and its leadership.
We are pleased to announce that Dr. Kostas Trakas has been appointed CEO of Exactis Innovation, effective February 1, 2022
Dr. Kostas Trakas joins Exactis from Noviscend Inc. where he was CEO and co-founder. Noviscend is a healthcare company distributing innovative medical technologies in Canada. Kostas was also the Principal Consultant at Prometheus Healthcare Strategies. Prior to that, he was co-founder of Nutu, a digital health company.
Kostas brings 14 years of global commercial experience in the pharmaceutical industry where most recently he was a Global Marketing Leader for Janssen’s (J&J) Infectious Disease &am Vaccines.
At Janssen (J&J), he was part of two transformational business experiments. Each business was created to leverage commercial opportunities in the emerging healthcare ecosystem. Kostas brings more than 10 years of market access expertise across multiple treatment modalities, geographies, and therapeutic fields. Kostas earned his Ph.D. in Pharmacology from the University of Toronto.
Please join us in welcoming Dr. Kostas Trakas to Exactis Innovation.
After 8 years with Exactis and over 35 years in the biomedical sector, I will be stepping down as CEO to focus on another strategic priority. I will report to the Board of Directors and support the new leadership to ensure that Exactis continues its mission and evolution relative to sector trends and demands.
I have been fortunate throughout my career to have worked with many outstanding individuals to build the Exactis network, infrastructure, and research program. I thank all of you for rallying around our common mission to advance precision oncology research in Canada with the goal of improving patient outcomes. Today, Exactis is a network comprised of 16 major cancer centers with a patient registry of over 8,000 participants and successful studies in precision medicine. It has been a wonderful journey and I am proud to have had the opportunity to be so closely involved with you over the past 8 years.
Sincerely,
Richard Fajzel